SER vs XTLB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SER is a Sell and XTLB is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SER’s FA Score shows that 1 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).
- SER’s FA Score: 1 green, 4 red.
- XTLB’s FA Score: 0 green, 5 red.
Price Growth
SER (@Biotechnology) experienced а +10.78% price change this week, while XTLB (@Biotechnology) price change was +0.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.
Reported Earning Dates
SER is expected to report earnings on Mar 31, 2023.
XTLB is expected to report earnings on Dec 03, 2024.
Industries' Descriptions
@Biotechnology (-8.58% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| SER | XTLB | SER / XTLB | |
| Capitalization | 42.9M | 10.1M | 425% |
| EBITDA | N/A | 630K | - |
| Gain YTD | 1154.545 | 83.150 | 1,389% |
| P/E Ratio | 30.53 | N/A | - |
| Revenue | N/A | 0 | - |
| Total Cash | 6.06M | 133K | 4,559% |
| Total Debt | 11.7M | N/A | - |
SER | XTLB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | |
SMR RATING 1..100 | 100 | 91 | |
PRICE GROWTH RATING 1..100 | 35 | 60 | |
P/E GROWTH RATING 1..100 | 31 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XTLB's Valuation (60) in the Biotechnology industry is in the same range as SER (63) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.
XTLB's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.
XTLB's SMR Rating (91) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.
SER's Price Growth Rating (35) in the null industry is in the same range as XTLB (60) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.
SER's P/E Growth Rating (31) in the null industry is significantly better than the same rating for XTLB (100) in the Biotechnology industry. This means that SER’s stock grew significantly faster than XTLB’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| IUEFX | 25.40 | -0.20 | -0.78% |
| JPMorgan International Focus R5 | |||
| SBHVX | 16.23 | -0.19 | -1.16% |
| Segall Bryant & Hamill Sm Cp Val Ins | |||
| OIGIX | 35.74 | -0.44 | -1.22% |
| Invesco Oppenheimer International Gr R6 | |||
| MEFOX | 59.89 | -1.10 | -1.80% |
| Meehan Focus | |||
| BSDKX | 13.55 | -0.32 | -2.31% |
| BlackRock SMID-Cap Growth Equity K | |||
SER and
Correlation & Price change
A.I.dvisor indicates that over the last year, SER has been closely correlated with LIANY. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SER jumps, then LIANY could also see price increases.
| Ticker / NAME | Correlation To SER | 1D Price Change % | ||
|---|---|---|---|---|
| SER | 100% | -3.40% | ||
| LIANY - SER | 69% Closely correlated | N/A | ||
| GERN - SER | 65% Loosely correlated | -1.35% | ||
| XTLB - SER | 59% Loosely correlated | +1.65% | ||
| OTLK - SER | 38% Loosely correlated | -1.81% | ||
| ELVN - SER | 37% Loosely correlated | -2.05% | ||
More | ||||
XTLB and
Correlation & Price change
A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.
| Ticker / NAME | Correlation To XTLB | 1D Price Change % | ||
|---|---|---|---|---|
| XTLB | 100% | +1.65% | ||
| SER - XTLB | 59% Loosely correlated | -3.40% | ||
| ADTX - XTLB | 27% Poorly correlated | -7.32% | ||
| BCRX - XTLB | 25% Poorly correlated | -5.64% | ||
| CRNX - XTLB | 25% Poorly correlated | -8.28% | ||
| VRCA - XTLB | 25% Poorly correlated | -3.45% | ||
More | ||||